The gene therapy for multiple sulfatase deficiency was one of the preclinical programs the Bespoke Gene Therapy Consortium selected for its pilot.
Houston biopharma company CoRegen said it has received US Food and Drug Administration clearance to begin a Phase I/II trial of CRG-150, an adoptive cell therapy targeting steroid receptor coactivator ...
Spur Therapeutics on Tuesday said it has treated the first Gaucher disease patient with its investigational gene therapy, FLT201 (avigbagene parvec), in a pivotal trial. In the Phase III GALILEO-3 ...
The firm said it will use the funds to advance its KRAS-targeted cancer vaccine ELI-002 7P in KRAS-driven pancreatic cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results